… bronchodilators, such as albuterol or ipratropium [1]. The objective of this article is to review
the evidence supporting the use of combination therapy … long-acting bronchodilators, for the …

… This meta-analysis suggests that patients on single long-acting bronchodilator therapy or
LABA/LAMA combination therapy, who still have exacerbations and have blood eosinophil …

… Guidelines recommend combination therapy involving two long-acting bronchodilators
with differing modes of action in patients whose COPD is not sufficiently controlled with …

… therapies appears modest at best. Research and development of a new therapy, such as
triple combination therapy, … We did not consider triple combination therapy (ie LABA/LAMA/ICS) …

… The rationale for combination therapy, however, is less clearcut in the use of bronchodilators…
information that supports the use of combined bronchodilator therapy in patients with COPD. …

Background Several new fixed-dose combination bronchodilators have been recently launched,
and assessing their efficacy relative to each other, and with open dual combinations is …

… of combination therapy with albuterol and … albuterol, or these two agents in combination.
Participants were required to have a smoking history of at least 10 pack-years and a therapeutic …

… combined inhaled bronchodilator therapy slightly increased theiroverall use of inhaled
bronchodilators. … does not significantly affect marketgrowth for combination therapy beyond that …

… greater bronchodilator effect (90 mL greater FEV 1 at 90 min) when combination therapy with
… Despite our results, one should not conclude that combination therapy has no role in acute …

… to judge the efficacy of combination therapy based on MCIDs … bronchodilator is an insufficient
criterion on which to judge efficacy. We propose that, in evaluating combination therapy, …